PEL

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 47758 lacs for quarter ending on 30-SEP-2011 against Rs. 73141 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 5243 lacs for the quarter ending on 30-SEP-2011 against Rs. 1254044 lacs for the quarter ending on 30-SEP-2010.

Piramal Healthcare Limited has submitted to the Exchange the Consolidated Financial Results for the period ended September 30,2011.

Piramal Healthcare Limited has informed the Exchange regarding a press release dated October 20, 2011 , titled "Piramal Healthcare announces Q2FY2012 results, Total operating income up by 32% to Rs 535 crores for continuing businesses, Operating Profit was Rs 130 crores, Net Profit for the quarter was Rs 52 crores".

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 26568 lacs for quarter ending on 30-SEP-2011. Net Profit / (Loss) of Rs. 9539 lacs for the quarter ending on 30-SEP-2011.

Piramal Healthcare Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Piramal Healthcare Limited has informed the Exchange that the Annual General Meeting of the members of the Company held on August 09, 2011 has approved the following: (1) The Audited Accounts for the year ended March 31, 2011 were adopted. (2) Dividend at Rs. 12/- per equity share of Rs.2/- (i.e. @ 600%) on 16,72,10,515 Equity Shares was declared for the financial year ended March 31, 2011. (3) Mr. Y. H. Malegam and Mr. Deepak Satwalekar have been reappointed as Directors of the Company. (4) M/s. Price Waterhouse, Chartered Accountants, Mumbai have been reappointed as Auditors of the Company.

Piramal Healthcare Limited has informed the Exchange regarding a press release dated August 10, 2011, titled "Piramal Healthcare To Acquire 5.5% Stake in Vodafone Essar".

Piramal Healthcare Limited has informed the Exchange regarding a press release dated August 02, 2011, titled "Piramal Healthcare announces Q1FY2012 results, Total operating income up by 35% to Rs.512 crores for continuing businesses, Operating Profit was higher at Rs.155 crores, Net Profit for the quarter up to Rs.89 crores".

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 44098 lacs for quarter ending on 30-JUN-2011 against Rs. 84241 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 8923 lacs for the quarter ending on 30-JUN-2011 against Rs. 8074 lacs for the quarter ending on 30-JUN-2010.

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 25550 lacs for quarter ending on 30-JUN-2011 against Rs. 57036 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 10109 lacs for the quarter ending on 30-JUN-2011 against Rs. 6691 lacs for the quarter ending on 30-JUN-2010.

Piramal Healthcare Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2011.

Piramal Healthcare Limited has informed the Exchange that by an Order made on July 08, 2011, in Piramal Healthcare Limited ("the Applicant Company") Summons for Directions, the Hon'ble High Court of Judicature at Bombay has directed that a meeting of the Equity Shareholders of Piramal Healthcare Limited, the Applicant Company, be convened and held on August 09, 2011 for the purpose of considering and, if thought fit, approving with or without modification(s), the proposed arrangement embodied in the Scheme of Arrangement between Piramal Life Sciences Limited and Piramal Healthcare Limited and

Piramal Healthcare Limited has informed the Exchange that Mr. Amit Chandra has been appointed as an Additional Director on the Board of the Company.

Piramal Healthcare Limited has informed the Exchange regarding the outcome of Board Meeting held on May 06, 2011.

Piramal Healthcare Limited has informed the Exchange regarding Press Releases dated May 06, 2011 titled :" Piramal Healthcare announces Q4FY2011 results, Total operating income up by 62% to Rs. 689 crores, Operating Profit was higher at Rs. 263 crores, Net Profit for the quarter up to Rs. 202 crores" and "Piramal Life Sciences Limited and Piramal Healthcare Limited- Demerger of the NCE Research Unit of Piramal Life Science Limited into Piramal Healthcare Limited"

Piramal Healthcare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 06, 2011 has recommended dividend of Rs.6 per equity share of face value of Rs.2/- (i.e. @ 300%) for the financial year ended March 31, 2011. In addition to this, the Board has also recommended a one-time Special Dividend of Rs.6 per equity share of face value of Rs.2/- (i.e. @ 300%) as a further reward to shareholders consequent to the sale of the Domestic Formulations Business which took place during the financial year ended March 31, 2011. The total dividends (i.e. norm

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 250986 lacs for year ending on 31-MAR-2011 against Rs. 367105 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 1288336 lacs for the year ending on 31-MAR-2011 against Rs. 48190 lacs for the year ending on 31-MAR-2010.

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 158536 lacs for year ending on 31-MAR-2011 against Rs. 266621 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 1289691 lacs for the year ending on 31-MAR-2011 against Rs. 44322 lacs for the year ending on 31-MAR-2010.

Piramal Healthcare Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Neeraj Katare has submitted to the Exchange a copy of Disclosure under Regulation 13(4) of SEBI (Prohibition of Insider Trading) Regulation 1992- change in its shareholding pursuant to Buyback of Shares through Tender offer.

News Verification : The media had reports that Piramal Healthcare Limited may buy Mafatlal Industries Limited's 7 acre plot in Central Mumbai. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Healthcare Limited has vide its letter inter-alia stated, "We would like to clarify that the said news article does not pertain at all to the Company. The Company is not buying any land from Mafatlal Industries Limited."

Kotak Mahindra Capital Company Limited has submitted to the Exchange a copy of the Post Buyback Public Announcement with respect to Buyback of 41,802,629 equity shares of Rs.2/- each by Piramal Healthcare Limited through a Tender Offer at a Price of Rs.600/- per share that has been released in the newspaper on March 31, 2011.

Piramal Healthcare Limited has informed the Exchange vide its letter dated March 29, 2011 regarding "Buyback of 41,802,629 equity shares of Rs. 2/- each by Piramal Healthcare Limited through a Tender Offer at a Price of Rs. 600/- per share".

News Verification : The media had reports that Piramal Healthcare Limited. may merge Piramal Lifesciences Limited with itself. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Healthcare Limited has vide its letter inter-alia stated, "We would like to state that the Company explores various strategic moves from time to time. However, as a policy and in the interest of its shareholders, the Company does not comment on any rep

Kotak Mahindra Capital Company Limited has submitted to the Exchange a copy of Corrigendum Public Announcement with respect to the Buyback of 41,802,629 equity shares of Rs.2/- each by Piramal Healthcare Limited ("company") through a Tender Offer at a price of Rs.600/- per share.

Piramal Healthcare Limited has informed the Exchange regarding a revised timeline for Buyback of 41,802,629 Equity Shares through a Tender Offer Route at a price of Rs. 600 per share.

Piramal Healthcare Limited has informed the Exchange regarding a press release dated February 11, 2011 , titled "Piramal Healthcare announces Q3FY2011 results, Total operating income up by 60% to Rs 534.9 crores for continuing businesses, Operating Profit was higher at Rs 114.1 crores, Net Profit for the quarter up to Rs 60.3 crores."

Piramal Healthcare Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2010.

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 40269 lacs for quarter ending on 31-DEC-2010 against Rs. 90770 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 6033 lacs for the quarter ending on 31-DEC-2010 against Rs. 13621 lacs for the quarter ending on 31-DEC-2009.

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 20980 lacs for quarter ending on 31-DEC-2010 against Rs. 70489 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 9202 lacs for the quarter ending on 31-DEC-2010 against Rs. 13828 lacs for the quarter ending on 31-DEC-2009.

Piramal Healthcare Limited has informed the Exchange with reference to the earlier Public Announcement dated December 09, 2010 regarding Buy Back of 41,802,629 equity shares through a Tender Offer Route at a price of Rs.600 per share that the Letter of Offer for the Buyback is in the process of finalisation and shall be dispatched once the Company have received the necessary regulatory clearances. Consequently, the Company will issue a Corrigendum to the PA ("Corrigendum") containing the revised timeline (including the Opening and Closing Dates) for the Buyback. The Corrigendum shall appear in

Kotak Mahindra Capital Company Limited has informed the Exchange regarding Public Announcement issued pursuant to and in accordance with the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 1998, as amended. The Buyback Offer : Piramal Healthcare Limited ("Company") hereby announces the buyback ("Buyback") of 41,802,629 fully paid-up equity shares of the face value of Rs.2/- each ("Shares") from the shareholders of the Company through a tender offer, in accordance with Section 77A and other applicable provisions of the Companies Act, 1956 ("Act"), the Securities and

Piramal Healthcare Limited has informed the Exchange vide its letter dated December 06, 2010 regarding the Results of Postal Ballot.

Piramal Healthcare Limited has informed the Exchange that pursuant to the provisions of Section 192A of the Companies Act, 1956 ("the Act") read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, that the following resolutions are proposed to be passed by way of postal Ballot: 1) Special Resolution under section 77A of the Companies Act,1956, for purchase of a maximum of 4,18,02,629 equity shares of the Company (representing 20% of the total number of shares), from the shareholders on a proportionate basis through the "Tender Offer" route as prescribed under the Secur

Piramal Healthcare Limited has informed the Exchange that the Board of Directors at its meeting held on October 22, 2010 after considering various alternatives, including Interim Dividend and/or Buy-back of Shares, and considering the fact that Buy-back is a better tax efficient method of maximizing value to shareholders, have approved Buy-back proposal for purchase by the Company of a maximum of 4,18,02,629 equity shares of face value Rs.2 each (representing 20% of the total number of shares), from the shareholders of the Company on a proportionate basis through the Tender Offer route as pres

Piramal Healthcare Limited has informed the Exchange regarding a press release dated October 22, 2010 titled "Piramal Healthcare completes sale of its domestic formulation business and its shareholding in Piramal Diagnostic Services Pvt.Ltd.; PHL to rewards shareholders with buyback of upto 20% of outstanding share capital at Rs.600 per share".

Piramal Healthcare Limited has informed the Exchange regarding the outcome of the Meeting of the Board of Directors of the Company held on October 22, 2010.

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 75201 lacs for quarter ending on 30-SEP-2010 against Rs. 99999 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 1254044 lacs for the quarter ending on 30-SEP-2010 against Rs. 10627 lacs for the quarter ending on 30-SEP-2009.

Piramal Healthcare Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2010.

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 54004 lacs for quarter ending on 30-SEP-2010 against Rs. 70770 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 1256998 lacs for the quarter ending on 30-SEP-2010 against Rs. 11422 lacs for the quarter ending on 30-SEP-2009.

Piramal Healthcare Limited has submitted to the Exchange a copy of Disclosure under Regulation 13(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 and Regulation 7(3) of Securities and Exchange Board of India (substantial Acquisition of shares and takeovers) Regulations, 1997

Piramal Healthcare Limited has informed the Exchange regarding a press release dated September 08, 2010, titled "Piramal Healthcare Limited Announces Completion of the Sale of its Domestic Formulations Business to Abbott Healthcare Private Limited".

Adelwise Investments Private Limited had submitted to the Exchange a copy of Disclosure under Regulation 3(3) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997. The Company has now informed the Exchange that "We do not wish to proceed with the proposed acquisition of shares of Piramal Healthcare Limited".

Cavaal Fininvest Private Limited has submitted to the Exchange a copy of Disclosure under Regulation 3(3) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Adelwise Investments Private Limited has submitted to the Exchange a copy of Disclosure under Regulation 3(3) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Piramal Healthcare Limited had informed the Exchange that the Company has signed a definitive agreement under which, Super Religare Laboratories Limited ('SRL') would acquire Piramal Diagnostic Services Private Limited ("PDSL"), a subsidiary of the Company. The Company has now informed the Exchange vide its letter dated August 21, 2010, that the Company has now completed the divestiture of its shareholding in PDSPL to SRL.

BMK Laboratories Private Limited has submitted to the Exchange a copy of Disclosure under Regulation 3(3) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Paramount Pharma Private Limited has submitted to the Exchange a copy of Disclosure under Regulation 3(3) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Piramal Healthcare Limited has informed the Exchange regarding a press release dated August 10, 2010 titled "Piramal Healthcare reports Q1FY2011 results".

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 57036 lacs for quarter ending on 30-JUN-2010 against Rs. 56973 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 6691 lacs for the quarter ending on 30-JUN-2010 against Rs. 7411 lacs for the quarter ending on 30-JUN-2009.